Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Worster-Drought Syndrome (Congenital Bilateral Perisylvian Syndrome) with Posterior Pituitary Ectopia, Pituitary Hypoplasia, Empty Sella and Panhypopituitarism: A Patient Report.
Baş F, Darendeliler F, Zuhal Yapici Z, Gokalp S, Bundak R, Saka N, Günöz H. Baş F, et al. Among authors: saka n. J Pediatr Endocrinol Metab. 2023 Nov 2;19(4):535-540. doi: 10.1515/jpem-2006-190412. Print 2006 Apr 1. J Pediatr Endocrinol Metab. 2023. PMID: 38742786 No abstract available.
Expanding the Scope: In-depth Review of Interaction in Regression Models.
Shiroshita A, Yamamoto N, Saka N, Shiba H, Toki S, Yamamoto M, Dohi E, Kataoka Y. Shiroshita A, et al. Among authors: saka n. Ann Clin Epidemiol. 2023 Jun 10;6(2):25-32. doi: 10.37737/ace.24005. eCollection 2024. Ann Clin Epidemiol. 2023. PMID: 38606039 Free PMC article. No abstract available.
Withdrawal notice to: "Gastroretentive fibrous dosage forms for prolonged delivery of sparingly soluble tyrosine kinase inhibitors. Part 2: Experimental validation of the models of expansion, mechanical strength, and in vitro drug release" [Int. J. Pharm. 653 (2024) 123429].
Blaesi AH, Saka N. Blaesi AH, et al. Among authors: saka n. Int J Pharm. 2024 Mar 25;653:124020. doi: 10.1016/j.ijpharm.2024.124020. Epub 2024 Mar 22. Int J Pharm. 2024. PMID: 38521692 No abstract available.
Withdrawal notice to: "Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 4: Experimental validation of the models of in vivo expansion, gastric residence time, and drug concentration in blood" [Int. J. Pharm. 653 (2024) 123479].
Blaesi AH, Saka N. Blaesi AH, et al. Among authors: saka n. Int J Pharm. 2024 Mar 25;653:124022. doi: 10.1016/j.ijpharm.2024.124022. Epub 2024 Mar 22. Int J Pharm. 2024. PMID: 38521691 No abstract available.
Withdrawal notice to: "Gastroretentive fibrous dosage forms for prolonged delivery of sparingly soluble tyrosine kinase inhibitors. Part 3: Theoretical models of in vivo expansion, gastric residence time, and drug concentration in blood" [Int. J. Pharm. 653 (2024) 123478].
Blaesi AH, Saka N. Blaesi AH, et al. Among authors: saka n. Int J Pharm. 2024 Mar 25;653:124021. doi: 10.1016/j.ijpharm.2024.124021. Epub 2024 Mar 22. Int J Pharm. 2024. PMID: 38521690 No abstract available.
Withdrawal notice to: "Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 1: Dosage form design, and models of expansion, post-expansion mechanical strength, and drug release" [Int. J. Pharm. 653 (2024) 123428].
Blaesi AH, Saka N. Blaesi AH, et al. Among authors: saka n. Int J Pharm. 2024 Mar 25;653:124019. doi: 10.1016/j.ijpharm.2024.124019. Epub 2024 Mar 22. Int J Pharm. 2024. PMID: 38521689 No abstract available.
173 results